A retrospective study long-term survival outcomes with immune checkpoint inhibitors in metastatic uveal melanoma
Latest Information Update: 29 Jul 2021
At a glance
- Drugs Ipilimumab (Primary) ; Ipilimumab/nivolumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Uveal melanoma
- Focus Therapeutic Use
- 29 Jul 2021 New trial record
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology